Navigation Links
Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round

OXFORD, England, February 10 /PRNewswire/ -- Glide Pharma, a specialty pharmaceutical company focused on the needle-free administration of solid dose therapeutics and vaccines, today announced that it has completed an oversubscribed GBP2.7 million ($4.3 million) investment round. The fundraising was supported by a number of existing institutional and private investors, including Hygea VCT and Oxford Technology VCTs. The company has now completed four successful investment rounds, securing funding totalling approximately GBP10 million. Glide will use the new funds to progress its in-house Glide octreotide programme into clinical development and to continue scale-up of its commercial manufacturing process.

The investment follows the recent successful clinical proof-of-concept of Glide Pharma's proprietary solid dose injector, the Glide SDI(R). The clinical study, conducted in 18 subjects with a solid dose formulation of the analgesic fentanyl, confirmed that the Glide SDI can safely and quickly deliver accurate doses into the systemic circulation, demonstrating the potential of the Glide technology in the $2 billion per annum breakthrough pain market. Throughout the study, administration with the needle-free Glide SDI avoided the bruising and bleeding associated with needle and syringe delivery.

"The completion of this oversubscribed fundraising is a clear demonstration of our investors' confidence in the Glide technology and the advantages it can offer both patients and our partners in the pharmaceutical industry," said Dr Charles Potter, Glide Pharma's CEO. "Glide has made great progress recently, having achieved clinical proof-of-concept with our proprietary solid dose injection system, and extending our pipeline of programmes with pharmaceutical partners. We aim to build on this strong foundation in the coming months by accelerating our second in-house project, Glide octreotide, into the clinic."

About Glide Pharma

Glide Pharma is a specialty pharmaceutical company focused on the easy, safe and convenient administration of solid dose formulations of therapeutics and vaccines. The company has a range of in-house and partnered programmes based on its proprietary needle-free solid dose injector, the Glide SDI(R).

Glide has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors. The company has successfully completed four investment rounds, and is supported by a consortium of institutional and private technology investors, including Oxford Capital Partners, Hygea VCT and Oxford Technology Venture Capital Trusts.

About the Glide SDI(R) solid dose injector

The Glide SDI is an innovative needle-free delivery system. The reusable injector utilises a spring mechanism to rapidly administer medicines, in the form of a tiny granule supplied in a pre-filled disposable cassette, below the patient's skin where it dissolves and enters the circulation.

The one-click action, pen-sized device is extremely easy to use, making it ideal for self administration. In clinical testing, volunteers strongly preferred the Glide SDI to the traditional needle and syringe. Additionally, Glide solid dose formulations offer the potential to improve the stability and to modify the release of medicines into the bloodstream, avoid time-consuming reconstitution and eliminate the risk of needle-stick injuries.


    Charles Potter
    Glide Pharma Tel:
    Tel: +44(0)8700-853700

    Rob Budge
    RJB Communications
    Mobile: +44(0)7710-741241

SOURCE Glide Pharma

SOURCE Glide Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Verathon Introduces the GlideScope(R) Cobalt Advanced Video Laryngoscope (AVL); New Digital Technology Facilitates Quick Intubations
2. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
3. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
4. ISTA Pharmaceuticals Announces 2010 Financial Guidance
5. DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv
6. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
7. Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP
8. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
9. Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
10. Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
11. Babson Executive Education Offers Bio-Pharma: Mastering the Business of Science
Post Your Comments:
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):